J. Goldman & Co LP Buys New Position in Axsome Therapeutics, Inc. $AXSM

J. Goldman & Co LP bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 23,014 shares of the company's stock, valued at approximately $5,633,000.

A number of other hedge funds have also recently bought and sold shares of the stock. ABS Investment Management LLC bought a new position in shares of Axsome Therapeutics in the second quarter valued at $171,339,000. Hsbc Holdings PLC acquired a new position in shares of Axsome Therapeutics in the second quarter valued at $13,667,000. PDT Partners LLC bought a new position in shares of Axsome Therapeutics in the second quarter valued at about $514,000. Palisade Capital Management LP acquired a new stake in shares of Axsome Therapeutics during the 2nd quarter worth about $6,153,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Axsome Therapeutics during the 2nd quarter worth about $55,171,000. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Trading Up 0.0%

Shares of AXSM stock opened at $205.48 on Wednesday. The stock has a 50 day simple moving average of $230.24 and a 200 day simple moving average of $206.43. Axsome Therapeutics, Inc. has a 1 year low of $112.90 and a 1 year high of $260.19. The company has a current ratio of 1.43, a quick ratio of 1.34 and a debt-to-equity ratio of 1.52. The stock has a market cap of $10.76 billion, a P/E ratio of -54.79 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The company had revenue of $218.38 million for the quarter, compared to the consensus estimate of $221.11 million. On average, research analysts predict that Axsome Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

AXSM has been the subject of several research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Axsome Therapeutics in a research report on Friday, July 17th. Jefferies Financial Group reiterated a "buy" rating and set a $380.00 target price on shares of Axsome Therapeutics in a research note on Thursday, June 11th. Deutsche Bank Aktiengesellschaft set a $280.00 price target on Axsome Therapeutics in a report on Tuesday, May 5th. BMO Capital Markets began coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an "outperform" rating and a $310.00 price objective on the stock. Finally, Royal Bank Of Canada dropped their target price on Axsome Therapeutics from $304.00 to $297.00 and set an "outperform" rating for the company in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $267.60.

Insider Activity

In related news, CEO Herriot Tabuteau sold 49,670 shares of the stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $241.01, for a total transaction of $11,970,966.70. Following the sale, the chief executive officer owned 7,229 shares in the company, valued at approximately $1,742,261.29. This trade represents a 87.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Nick Pizzie sold 33,000 shares of the company's stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total value of $7,922,970.00. Following the sale, the chief financial officer owned 42,867 shares of the company's stock, valued at $10,291,938.03. The trade was a 43.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 200,766 shares of company stock valued at $46,685,646 in the last 90 days. 20.60% of the stock is owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source